Safety and efficacy of quadruple induction regimen with basiliximab, everolimus, mycophenolate and very low dose tacrolimus in comparison with conventional standard triple regimen in post-transplant patients
Latest Information Update: 07 Oct 2016
At a glance
- Drugs Tacrolimus (Primary) ; Basiliximab; Everolimus; Mycophenolate
- Indications Graft-versus-host disease; Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 07 Oct 2016 New trial record